Scottsdale 4/15/2015 8:00:00 PM
News / Finance

QualityStocks News - International Stem Cell Corp. (ISCO) to Present Final Safety and Efficacy Results from Parkinson’s Disease Program at AAN Annual Meeting

QualityStocks would like to highlight International Stem Cell Corporation (OTCQB: ISCO), researching the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). The company is focused on using these stem cells to treat diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells or tissue.

In the company’s news,

International Stem Cell Corp., a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced that it will be giving a platform presentation on its preclinical studies in Parkinson’s at the 2015 American Academy of Neurology Annual Meeting in Washington, DC. Ruslan Semechkin, Ph.D., ISCO’s chief scientific officer, will discuss the data at the “Parkinson’s Disease” scientific session (s48.007), on Thursday, April 23rd at 4:45 pm in a talk entitled “Neural Stem Cell Based Therapy for Parkinson’s Disease.”

“These animal studies strongly suggest that the transplantation of human parthenogenetic neural stem cells (hpNSCs), for the treatment of Parkinson’s will be efficacious, safe and well tolerated,” stated Ruslan Semechkin, Ph.D. “The data further elucidate our platform and help solidify expectations for our planned Phase 1/2a studies in humans.”

The data presented are from two safety studies, where human parthenogenetic neural stem cells (hpNSC) were transplanted into the brains of healthy animals, and a proof-of-principle study where the cells were transplanted into animals with induced Parkinson’s disease symptoms. The studies show that hpNSCs migrated to the injured brain area, increased dopamine levels, protected and recovered neurons and improved the motor function. Additionally, at the conclusion of the twelve month non-human primate safety study, no evidence of teratoma formation or ectopic tissue was found in any animals that received the human cell transplants.

ISCO has built a comprehensive preclinical safety dataset from a series of GLP and non-GLP studies on hpNSC. The Company has submitted a CTX application to the Australian regulatory authorities and plans to begin the phase 1/2a clinical study within the next few months.

For those not familiar with them, hpNSCs are a novel therapeutic cellular product derived from International Stem Cell Corporation’s proprietary human pluripotent stem cells. Neural stem cells work to repair the brain in several ways. The cells are attracted to the site of injury and in response to signals released by the damaged tissue release a range of molecules that reduce inflammation and trigger the recovery process. Neural stem cells also have the ability to generate new cells to replace those that are either dead or dying enabling the formation of new tissue. In this way the hpNSCs act as coordinators of all the various activities necessary to recover brain function.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit  

To connect with QualityStocks via Facebook, please visit

To connect with QualityStocks via Twitter, please visit

Please read FULL disclaimer on the QualityStocks website:   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.